Insider trading disclosures filed this week reveal a concentrated pattern of activity in a handful of US-listed companies, with substantial purchases at medical device and lab-equipment names and large disposals by private investment firms and corporate directors. Below is a detailed accounting of the most significant reported transactions, followed by an assessment of the immediate context provided in the filings.
Top buys
PROCEPT BioRobotics Corp - The largest insider purchase reported on Tuesday was disclosed for PROCEPT BioRobotics Corp, where a director, Rohit Desai, purchased shares totaling just over $10.4 million across multiple trades executed between March 5 and March 9, 2026. The acquisitions were made at prices that ranged from $23.3282 to $26.4073 per share. The filing details the individual tranches: on March 5, Desai acquired 142,498 shares in one trade and 24,748 shares in another; on March 6, he purchased 106,554 shares and 53,763 shares; and on March 9, he added 43,581 shares, 53,818 shares and 1,300 shares. The company’s common stock is trading at $25.26, a level that represents a 57% decline over the past year. According to InvestingPro analysis cited in the filing, PROCEPT appears undervalued at current market levels.
Eastern Co - Barington Companies Equity Partners L.P. reported purchases totaling 7,409 common shares across two transactions executed on March 6 and March 9, 2026. The shares were bought at prices between $18.2867 and $18.7426, producing an aggregate cash outlay of $136,553. The filing specifies that 5,067 shares were purchased on March 6 and 2,342 shares on March 9. After these purchases, Barington Companies Equity Partners L.P. indirectly holds 642,342 shares. The filing also notes that James A. Mitarotonda, identified as a director and a ten percent owner, directly owns 42,794 shares. Eastern Co’s shares are quoted at $19.21, trading near a 52-week low of $17.61. InvestingPro commentary cited in the disclosure lists the stock among those the service classifies as Most Undervalued and highlights the company’s 56 consecutive years of dividend payments and a current dividend yield of 2.31%.
Grocery Outlet Holding Corp - Director John E. Bachman reported buying a total of 16,000 shares on March 6, 2026, for a combined cost of $103,314. The Form 4 filing breaks the purchase into two tranches: 4,558 shares at $6.45 each and 11,442 shares at $6.46 each. The filing indicates these purchases were reported on a standard SEC disclosure.
Mesa Laboratories Inc - Director Mark Christopher Capone acquired 1,301 shares on March 10, 2026, at $76.35 per share, for an aggregate purchase price of $99,331. The filing shows the transaction occurred as the stock had recently fallen nearly 20% over the prior week and was trading at $73.47 at the time of reporting. InvestingPro analysis referenced in the disclosure characterizes Mesa Laboratories (MLAB) as appearing undervalued at current levels and assigns a "GOOD" financial health score of 2.71. Following the transaction, Capone directly holds 3,429 shares. Additional InvestingPro notes mentioned in the filing include nine exclusive tips for MLAB, among them observations regarding high shareholder yield and a 24-year consecutive dividend payment record.
Tecnoglass Inc - Director Anne Louise Carricarte reported the purchase of 1,100 ordinary shares on March 6, 2026, at a price of $43.275 per share, for a total investment of $47,602. The filing states the transaction was disclosed on a Form 4. The company’s stock is trading near a 52-week low of $40.09 and has declined 40% over the past six months. InvestingPro analysis cited in the disclosure describes the stock as appearing undervalued at current market levels. After the purchase, Carricarte directly owns 1,100 shares of Tecnoglass.
Top sells
Mercury Systems Inc - Jana Partners Management, LP disclosed the sale of 452,057 shares of common stock over three days, generating proceeds of approximately $41.4 million. The sales took place between March 2 and March 4, 2026, with trade prices ranging from $89.68 to $94.05 per share. The filing provides a day-by-day breakdown: on March 2, Jana Partners sold 182,510 shares at $94.05 per share; on March 3, the firm sold 168,648 shares in multiple transactions at prices between $89.98 and $90.21; and on March 4, the firm sold 100,899 shares at prices between $89.65 and $89.72. The disclosure notes that Mercury Systems delivered a 110% total return over the past year. InvestingPro analysis cited in the filing suggests the stock is currently overvalued compared with its Fair Value. The filing also states the company was not profitable over the preceding twelve months but that analysts forecast it will report profitability in the current year.
Dell Technologies Inc - Director Ellen Jamison Kullman sold 151,246 shares of Class C common stock on March 6, 2026, across a series of transactions with prices from $144.51 to $145.92, netting about $21.8 million. The Form 4 also documents that Kullman exercised options to acquire 150,346 shares of Class C common stock at exercise prices of $13.60 and $13.98, representing $2,048,049 in cash paid on the option exercises. These combined moves are disclosed in the same reporting package to the SEC.
Hilltop Holdings Inc - Gerald J. Ford, listed as a ten percent owner, sold 259,771 shares of common stock on March 5, 2026, at a price of $37.9833 per share, for aggregate proceeds of approximately $9.8 million. The Form 4 details that post-transaction Ford directly owns 7,866.9598 shares. The filing further outlines indirect holdings: 98,789 shares held through the Turtle Creek Revocable Trust and 15,544,674 shares held through Diamond A Financial, L.P. Hilltop Holdings (HTH) is reported as trading at a price-to-earnings ratio of 13.75. InvestingPro commentary in the filing describes the stock as appearing undervalued at current prices. The disclosure also provides shareholder-oriented metrics tracked by InvestingPro, including a 2.18% dividend yield and ten consecutive years of dividend increases, along with references to eight additional ProTips for HTH.
SBC Medical Group Holdings Inc - Chairman and CEO Aikawa Yoshiyuki sold 4,422,900 shares of common stock on March 6, 2026, at $2.12 per share, generating proceeds of $9,376,548. The filing indicates the position was held indirectly through Aikawa Equity Management Co., Ltd. The company’s shares are reported to be trading at $3.75, which the filing states represents a 77% increase from the transaction price; the filing also notes the shares have declined 13% year-to-date. After the sale, Aikawa is listed as directly holding 82,404,460 shares and indirectly holding an additional 5,000,000 shares via GODO Kaisha Aikawa Investment. InvestingPro analysis included in the disclosure indicates SBC appears undervalued at the present market price, with a more comprehensive analysis available in the platform’s Pro Research Report.
Snowflake Inc - Director Michael L. Speiser sold 50,166 shares of common stock on March 6, 2026, in transactions priced between $173.147 and $175.933, for a reported total sale value of about $8.8 million. The filing states the company’s shares are trading at $182.84 and have declined 16.65% year-to-date. InvestingPro analysis cited in the filing suggests the shares remain undervalued relative to Fair Value. The disclosure notes the sales were executed under a pre-arranged 10b5-1 trading plan that Speiser adopted on December 27, 2024.
Context and takeaways
The filings released this week display a mix of confidence and liquidity-driven actions by insiders and investment firms. On the buy side, several directors and institutional holders increased positions in companies that InvestingPro commentary describes as undervalued, including PROCEPT BioRobotics, Eastern Co, Mesa Laboratories, Tecnoglass and Grocery Outlet. These purchases were made at reported prices and share counts detailed above.
On the sell side, large blocks were moved by a private equity investor and by senior executives and directors at several firms. The filings include conventional disclosures about indirect holdings and, in one case, the use of a 10b5-1 trading plan to execute a pre-arranged series of sales. Several of the companies where sales occurred have mixed metrics in the InvestingPro notes attached to the filings: some are flagged as overvalued relative to Fair Value, others are identified as undervalued despite the insider dispositions.
Monitoring insider activity can be one input among many when assessing companies. The filings underscore that insider sales may reflect a range of motives, including portfolio rebalancing, option exercises, or pre-planned disposition programs, while insider purchases are often interpreted as a signal of confidence in future prospects. The documents filed with the SEC provide precise dates, share counts and prices for each transaction, enabling market participants to track holdings and ownership changes among directors, officers and large shareholders.
Investors reviewing these disclosures should note the specifics recorded in the Form 4 filings and the accompanying InvestingPro commentary that is referenced in the filings. The raw figures and the stated post-transaction ownership levels give a factual basis for understanding how ownership stakes have shifted in each company.